Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study ; volume:102 ; number:8 ; day:10 ; month:6 ; year:2023 ; pages:2137-2151 ; date:8.2023
Annals of hematology ; 102, Heft 8 (10.6.2023), 2137-2151, 8.2023

Creator
Macro, M.
Hulin, C.
Vincent, L.
Charvet-Rumpler, A.
Benboubker, L.
Calmettes, C.
Stoppa, A.-M
Laribi, K.
Clement-Filliatre, L.
Zerazhi, H.
Honeyman, F.
Richez, V.
Maloisel, F.
Karlin, L.
Barrak, J.
Chouaid, C.
Leleu, X.
Contributor
SpringerLink (Online service)

DOI
10.1007/s00277-023-05278-3
URN
urn:nbn:de:101:1-2023101809333370648879
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Macro, M.
  • Hulin, C.
  • Vincent, L.
  • Charvet-Rumpler, A.
  • Benboubker, L.
  • Calmettes, C.
  • Stoppa, A.-M
  • Laribi, K.
  • Clement-Filliatre, L.
  • Zerazhi, H.
  • Honeyman, F.
  • Richez, V.
  • Maloisel, F.
  • Karlin, L.
  • Barrak, J.
  • Chouaid, C.
  • Leleu, X.
  • SpringerLink (Online service)

Other Objects (12)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Related objects